Cathepsin B expression and laminin degradation as factors influencing prognosis of surgically treated patients with lung adenocarcinoma.
We examined, immunohistochemically, tissues from primary lung adenocarcinomas. In 142 tumors, the mean overall labeling percentage of cathepsin B was 26.5 +/- 22.3 (SD). The mean labeling percentage of cathepsin B in cases with stage I disease was lower than that in cases with stages IIIA, IIIB, or IV disease (P < 0.05). Of the 115 tumors examined for laminin-positive basement membranes, 54 (47%) had a continuous pattern and 61 (53%) had a discontinuous pattern. The mean labeling percentage of cathepsin B was 35.0 +/- 24.2 in tumors with a discontinuous pattern, compared with the 21.9 +/- 16.9 in those with a continuous pattern (P < 0.01). The overall 5-year survival rates of patients with high and low cathepsin B expressions were 26% and 77%, respectively (P < 0.01), including 45% and 94% for patients with stage I disease, respectively (P < 0.01), and 15% and 60% for those with stage IIIB disease, respectively (P < 0.05). Multivariate analysis using the Cox life table regression model showed cathepsin B to be a significantly independent factor associated with death due to the disease. We conclude from this study that tumors with a discontinuous pattern of laminin have a higher percentage of cathepsin B, and the survival rate was poor for patients with a high expression of cathepsin B. Thus, cathepsin B may be useful in assessing prognosis in lung adenocarcinoma.